Digest Network Come funziona
Network
/
Società
Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

79 comunicati stampa

Guarda tutti i comunicati
23/10/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Industria
Web e Social Network
Telefonia e Varie
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
23/10/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Mercato azionario
Zai Lab Announces $250 Million Private Placement
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
21/10/2026
Scienza
HIV, AIDS e malattie autoimmuni
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
14/10/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Telefonia e Varie
Eventi
Industria
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
29/09/2026
Web e Social Network
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
17/08/2026
Industria
Biotecnologia
Farmaceutica
Salute
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
03/08/2026
Oncologia
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
22/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Oncologia
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
16/06/2026
Industria
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0